A phase II study of sintilimab plus anlotinib for Chinese patients (pts) with persistent, recurrent or metastatic cervical cancer (CC)

医学 内科学 肿瘤科 进行性疾病 临床终点 宫颈癌 实体瘤疗效评价标准 化疗 无进展生存期 癌症 转移 腺鳞癌 胃肠病学 腺癌 临床试验
作者
Qin Xu,Chuanben Chen,Yang Sun,Zhangzhou Huang,Yibin Lin,Jing Liu,Li Li,Zirong Li,Junping Pan,Ying Chen
出处
期刊:Gynecologic Oncology [Elsevier BV]
卷期号:162: S78-S78
标识
DOI:10.1016/s0090-8258(21)00787-3
摘要

Objectives: There are limited effective therapies for CC pts who have previously received multiple lines of chemotherapy. The combination of immune checkpoint inhibitors (ICIs) plus angiogenesis inhibitors has demonstrated significant anti-tumor activity in certain cancer. The goal of this study was to evaluate the efficacy and safety of sintilimab (a human programmed death-1 ICI) plus anlotinib (a multi-target tyrosine kinase inhibitor, inhibiting tumor angiogenesis and proliferative signaling) in persistent, recurrent or metastatic CC pts. Methods: Patients who have received at least once platinum-based systemic chemotherapy, recurrence or metastasis advanced cervical cancer (including squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma), more than 1% PD-L1 expression, ECOG 0-1 were considered eligible for enrollment. Sintilimab was administered intravenously (200mg once every 3weeks), and anlotinib was taken orally (10mg mg qd, d1-14, 21 days per cycle). The treatment was continued until disease progression, death or intolerant toxicity. The primary endpoint was objective response rate (ORR) and the secondary endpoints included disease control rate (DCR), progression-free survival (PFS), overall survival (OS) and safety. Results: From September 2019 to August 2020, 25 patients with FIGO stage I (8%), II (36%), III (44%), IV (4%) and undiagnosed (8%) were enrolled with a median age of 52 years old (range: 36-67). Among these patients, 17 patients were evaluable. The therapeutic evaluation showed the incidence of complete response, partial response, stable disease and progression disease was 11.8%, 58.8%, 29.4% and 0% respectively, yielding the ORR of 70.6% (95% CI: 44.0%-89.7%) and the DCR of 100% (95% CI: 80.5%-100.00%). The median PFS was not reached. Most of the occurring adverse events were grade 1 or 2, and >10% Grade 1 AEs included hyperlipemia (40.0%), hypothyroidism (20.0%), hypertension (16.0%), >10% Grade 2 AEs included hand-foot syndrome (12.0%). Intolerance was only observed in 1 patient. Conclusions: Sintilimab plus anlotinib showed a promising efficacy with a favorable toxicity profile for patients with persistent, recurrent or metastatic cervical cancer. We will report more data in the future. There are limited effective therapies for CC pts who have previously received multiple lines of chemotherapy. The combination of immune checkpoint inhibitors (ICIs) plus angiogenesis inhibitors has demonstrated significant anti-tumor activity in certain cancer. The goal of this study was to evaluate the efficacy and safety of sintilimab (a human programmed death-1 ICI) plus anlotinib (a multi-target tyrosine kinase inhibitor, inhibiting tumor angiogenesis and proliferative signaling) in persistent, recurrent or metastatic CC pts. Patients who have received at least once platinum-based systemic chemotherapy, recurrence or metastasis advanced cervical cancer (including squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma), more than 1% PD-L1 expression, ECOG 0-1 were considered eligible for enrollment. Sintilimab was administered intravenously (200mg once every 3weeks), and anlotinib was taken orally (10mg mg qd, d1-14, 21 days per cycle). The treatment was continued until disease progression, death or intolerant toxicity. The primary endpoint was objective response rate (ORR) and the secondary endpoints included disease control rate (DCR), progression-free survival (PFS), overall survival (OS) and safety. From September 2019 to August 2020, 25 patients with FIGO stage I (8%), II (36%), III (44%), IV (4%) and undiagnosed (8%) were enrolled with a median age of 52 years old (range: 36-67). Among these patients, 17 patients were evaluable. The therapeutic evaluation showed the incidence of complete response, partial response, stable disease and progression disease was 11.8%, 58.8%, 29.4% and 0% respectively, yielding the ORR of 70.6% (95% CI: 44.0%-89.7%) and the DCR of 100% (95% CI: 80.5%-100.00%). The median PFS was not reached. Most of the occurring adverse events were grade 1 or 2, and >10% Grade 1 AEs included hyperlipemia (40.0%), hypothyroidism (20.0%), hypertension (16.0%), >10% Grade 2 AEs included hand-foot syndrome (12.0%). Intolerance was only observed in 1 patient. Sintilimab plus anlotinib showed a promising efficacy with a favorable toxicity profile for patients with persistent, recurrent or metastatic cervical cancer. We will report more data in the future.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
木生离完成签到 ,获得积分10
刚刚
annzhang完成签到,获得积分10
1秒前
YONGHUMING完成签到,获得积分10
1秒前
1秒前
1秒前
lu2025发布了新的文献求助10
1秒前
林柒发布了新的文献求助10
1秒前
1秒前
豆子完成签到,获得积分10
2秒前
科研通AI6.2的应助被小普木采纳,获得10
2秒前
等待晓凡完成签到 ,获得积分10
2秒前
Xue0129发布了新的文献求助10
2秒前
辞旧完成签到,获得积分10
3秒前
3秒前
哇哇大叫发布了新的文献求助10
3秒前
碧蓝山水完成签到,获得积分10
3秒前
4秒前
朝盈完成签到,获得积分10
4秒前
4秒前
Pu发布了新的文献求助10
4秒前
科研通AI6.2的应助被无敌W采纳,获得10
4秒前
_L完成签到,获得积分10
4秒前
CodeCraft的应助被冷酷的汉堡采纳,获得10
5秒前
5秒前
加一份芋圆完成签到 ,获得积分10
5秒前
风吹麦浪的应助被糟糕的夏波采纳,获得10
5秒前
5秒前
小蘑菇的应助被zoey采纳,获得10
5秒前
太叔文博发布了新的文献求助10
6秒前
6秒前
晴朗完成签到,获得积分10
6秒前
YU发布了新的文献求助10
6秒前
菠萝吹雪完成签到 ,获得积分10
6秒前
大笨猪whr完成签到,获得积分10
6秒前
天天快乐的应助被听话的代芙采纳,获得10
6秒前
领导范儿的应助被kunnao采纳,获得10
7秒前
7秒前
liz完成签到,获得积分10
7秒前
无心的谷槐完成签到,获得积分20
7秒前
难过的煎饼完成签到,获得积分10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8159581
求助须知:如何正确求助?哪些是违规求助? 9555100
关于积分的说明 21724719
捐赠科研通 7749543
什么是DOI,文献DOI怎么找? 3427281
关于科研通互助平台的介绍 2552278
邀请新用户注册赠送积分活动 2471619